Grifols Doses First Patients in Two Phase 3 Trials to Expand Indications of its Flagship Immunoglobulins
Go back to Grifols Doses First Patients in Two Phase 3 Trials to Expand Indications of its Flagship Immunoglobulins| EAGLE CAPITAL GROWTH FUND, Inc. (NYSE: GRF) | Delayed: 10.34 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $10.34 | 52 Week High | $21.75 | |||
| Open | $10.34 | 52 Week Low | $6.41 | |||
| Day High | $10.34 | P/E | N/A | |||
| Day Low | $10.34 | EPS | $0.00 | |||
| Volume | 17 | |||||
| GRIFOLS SP ADR-B (NASDAQ: GRFS) | Delayed: 7.31 -0.09 (1.22%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $7.40 | 52 Week High | $35.35 | |||
| Open | $7.37 | 52 Week Low | $14.07 | |||
| Day High | $7.41 | P/E | N/A | |||
| Day Low | $7.29 | EPS | $0.00 | |||
| Volume | 367,746 | |||||
